OR52N4

Across TCGA pan-cancer cohorts, OR52N4 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated OR52N4 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher OR52N4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR52N4 expression acts as an unfavorable survival marker, although some lineages such as SKCM and LUSC show a favorable association.

STAD, COAD, and GBM are the cancer types where OR52N4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.003	0.688	<.001	36	view →
COAD	OS	Median	III,IV	0.054	0.793	<.001	12	view →
GBM	OS	Median	All	0.005	0.416	<.001	9	view →
HNSC	OS	Median	All	0.191	0.710	.021	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
ESCA	OS	Median	II,III,IV	0.277	0.686	.026	6	view →
SKCM	OS	Median	II,III,IV	0.964	0.828	.031	3	view →
LUSC	DFS	Median	All	0.773	0.383	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

OR52N4–STAD (OS)

Open the STAD breakdown →